Autoimmune diseases of the peripheral nervous system have so far been treated mainly with
exogenous high-dose intravenous immunoglobulins (IVIg), that act through several …

Simple Summary Cancer survivors can experience neurological complications after
exposure to anticancer therapy. Chemotherapy-induced peripheral neurotoxicity (CIPN) …

Abstract Disease Overview Waldenström macroglobulinemia (WM) is a lymphoplasmacytic
lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include …

Background and Objectives Neuropathy with antibodies to myelin-associated glycoprotein
(MAG) is the most common paraproteinemic IgM neuropathy. Recently, the mutational profile …

Despite advances in the treatment of chronic inflammatory demyelinating
polyradiculoneuropathy (CIDP) and other common autoimmune neuropathies (AN), still …

Objectives Ibrutinib is active in anti–myelin-associated glycoprotein (MAG) polyneuropathy
with MYD88L265P mutation; however, its efficacy is likely to be low in MYD88 wild-type …

The BTK inhibitors ibrutinib and acalabrutinib are FDA-approved drugs for the treatment of B
cell malignances. Both drugs have demonstrated clinical efficacy and safety profiles superior …

Simple Summary The peripheral nervous systems may be involved by several
hematological diseases ranging from preneoplastic diseases to overt malignancies or …

Chronic immune-mediated neuropathies, including chronic inflammatory demyelinating
polyradiculoneuropathy (CIDP), neuropathies associated with monoclonal gammopathy …

Autoimmune neuropathies are often treatable. First-line immunotherapies include
intravenous immunoglobulin (IVIG), plasma exchange and corticosteroids. However, nearly …